Puma Biotechnology (PBYI) Revenue (2017 - 2026)

Puma Biotechnology's Revenue history runs 10 years deep, the most recent figure standing at $44.8 million for Q1 2026.

• Quarterly Revenue fell 2.59% year-over-year to $44.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $227.2 million (down 2.38% YoY) and the FY2025 annual result came in at $228.4 million, down 0.91% from the prior year.
• Revenue was $44.8 million for Q1 2026 at Puma Biotechnology, down from $75.5 million in the prior quarter.
• Across five years, Revenue topped out at $87.6 million in Q4 2022 and bottomed at $43.8 million in Q1 2024.
• A 5-year average of $58.2 million and a median of $54.6 million in 2023 frame the typical range for Revenue.
• Peak annual rise in Revenue reached 58.33% in 2022, while the deepest fall reached 53.41% in 2022.
• Puma Biotechnology's Revenue stood at $87.6 million in 2022, then decreased by 17.65% to $72.2 million in 2023, then dropped by 18.15% to $59.1 million in 2024, then gained by 27.72% to $75.5 million in 2025, then slumped by 40.61% to $44.8 million in 2026.
• Business Quant data shows PBYI's Revenue at $44.8 million in Q1 2026, $75.5 million in Q4 2025, and $54.5 million in Q3 2025.